A novel trimeric triterpene, bismoronic ceramicine (1), was isolated from the bark of Chisocheton ceramicus Miq. The structure was elucidated based on spectroscopic data and chemical correlations. Bismoronic ceramicine (1) showed moderate antimalarial activity against Plasmodium falciparum strain 3D7.
The family Meliaceae has been known to produce various types of limonoids with medicinal properties.1–6 In the course of our continuing search for bioactive natural products from tropical plants,7–12 we have reported ceramicines from the bark of Malaysian Chisocheton ceramicus (Meliaceae).13–17 Ceramicine B showed a strong lipid droplet accumulation inhibitory activity on a mouse pre-adipocyte cell line (MC3T3-G2/PA6), and anti-melanin deposition activity against B16-F10 melanoma cells.18–20
In this paper, we report the isolation and structure elucidation of a novel trimeric triterpene, bismoronic ceramicine (1) from the bark of Chisocheton ceramicus Miq., and its antimalarial activity.
Bismoronic ceramicine (1) was obtained as an optically active colorless amorphous solid, [α] + 28 (c 1.0, CHCl3). The IR spectrum showed important absorptions at 3450, 1735, and 1703 cm−1 for hydroxyl, ester carbonyl, and ketone groups, respectively. The ESIMS (pos.) of 1 showed a molecular ion peak at m/z 1379 and the molecular formula of 1 was established as C87H126O13 from HRESIMS (pos.). The 1H and 13C NMR data (Supplemental Figures S1 and S2) (Table 1) and HSQC spectrum (Supplemental Figure S5) of 1 revealed the presence of 87 carbon signals due to 15 sp3 methines, 23 sp3 methylenes, 19 methyls, 17 sp3 quaternary carbons, five sp2 methines, three sp2 quaternary carbons, and five carbonyl carbons. Among them, six sp3 methines (δC 72.2; δH 4.15, δC 75.1; δH 4.35, δC 77.3; δH 3.73, δC 97.6; δH 6.50, δC 102.0; δH 6.19, δC 111.4; δH 4.68), one sp3 quaternary carbon (δC 78.3), and one methyl (δC 55.3; δH 3.40) were attributed to those attached to an oxygen atom. From the above data, 1 was presumed to be a trimeric triterpene (Figure 2; units A∼C).
Structure of bismoronic ceramicine (1).
Selected 2D NMR correlations of 1.
1H (600MHz) and 13C (150MHz) NMR Data of Bismoronic Ceramicine (1) in CDCl3 (δ in ppm, J in Hz).
no.
δH
δC
no.
δH
δC
no.
δH
δC
1
202.6
1′a
1.42 (1H, m)
39.8
1’’a
1.42 (1H, m)
39.8
1’b
1.96 (1H, m)
1’’b
1.96 (1H, m)
2
5.82 (1H, d, 9.8)
130.4
2’a
2.44 (1H, m)
34.1
2’’a
2.44 (1H, m)
34.1
2’b
2.49 (1H, m)
2’’b
2.49 (1H, m)
3
6.91 (1H, d, 9.8)
150.5
3’
218.1
3’’
218.5
4
45.9
4’
47.2
4’’
47.2
5
3.00 (1H, d, 12.8)
44.2
5’
1.33 (1H, m)
55.0
5’’
1.33 (1H, m)
54.8
6
4.35 (1H, dd, 12.8, 2.8)
75.1
6’
1.44 (1H, m)
19.6
6’’
1.44 (1H, m)
19.5
7
4.15 (1H, d, 2.8)
72.2
7’a
1.33 (1H, m)
33.8
7’’a
1.33 (1H, m)
33.7
7’b
1.46 (1H, m)
7’’b
1.48 (1H, m)
8
46.6
8’
40.6
8’’
40.5
9
2.46 (1H, m)
35.6
9’
1.33 (1H, m)
50.5
9’’
1.33 (1H, m)
50.4
10
46.6
10’
36.9
10’’
36.9
11a
1.67 (1H, m)
17.9
11’a
1.35 (1H, m)
21.3
11’’a
1.49 (1H, m)
21.2
11b
2.54 (1H, m)
11’b
1.53 (1H, m)
11’’b
1.55 (1H, m)
12a
1.58 (1H, m)
35.2
12’a
1.25 (1H, m)
26.1
12’’a
1.29 (1H, m)
26.1
12b
2.13 (1H, m)
12’b
1.61 (1H, m)
12’’b
1.55 (1H, m)
13
47.3
13’
2.27 (1H, brd, 12.6)
41.4
13’’
2.13 (1H, m)
41.3
14
158.4
14’
42.6
14’’
42.6
15
5.51 (1H, brs)
120.0
15’a
1.22 (1H, m)
29.1
15’’a
1.16 (1H, m)
29.0
15’b
1.65 (1H, m)
15’’b
1.56 (1H, m)
16a
2.08 (1H, m)
30.2
16’a
1.34 (1H, m)
33.4
16’’a
1.37 (1H, m)
33.2
16b
2.68 (1H, dd, 12.9, 12.9)
16’b
2.18 (1H, m)
16’’b
2.11 (1H, m)
17
2.07 (1H, m)
57.4
17’
48.3
17’’
47.8
18
1.23 (3H, s)
23.3
18’
137.4
18’’
136.3
19
1.13 (3H, s)
14.9
19’
5.18 (1H, s)
133.1
19’’
5.09 (1H, s)
132.9
20
78.3
20’
32.0
20’’
31.9
21
6.50 (1H, s)
97.6
21’
1.39 (2H, m)
33.5
21’’
1.36 (2H, m)
33.4
22
3.73 (1H, d, 6.4)
77.3
22’a
1.63 (1H, m)
33.1
22’’a
1.57 (1H, m)
33.0
22’b
2.00 (1H, m)
22’’b
1.90 (1H, m)
23
6.19 (1H, s)
102.0
23’
1.03 (3H, s)
21.0
23’’
1.03 (3H, s)
20.9
24’
1.07 (3H, s)
26.6
24’’
1.07 (3H, s)
26.8
25’
0.98 (3H, s)
16.5
25’’
0.97 (3H, s)
16.4
26’
1.01 (3H, s)
15.6
26’’
0.98 (3H, s)
15.9
27’
0.77 (3H, s)
14.7
27’’
0.75 (3H, s)
14.8
28
4.68 (1H, s)
111.4
28’
174.6
28’’
174.3
29
1.25 (3H, s)
18.3
29’
0.98 (3H, s)
30.3
29’’
0.94 (3H, s)
30.3
30
1.09 (3H, s)
26.2
30’
0.98 (3H, s)
29.1
30’’
0.92 (3H, s)
29.0
31
3.40 (3H, s)
55.3
The gross structure of 1 was elucidated by analysis of 2D NMR data, including 1H-1H COSY, HSQC, and HMBC spectra (Supplemental Figures S3, S5, and S6) in CDCl3 (Figure 2). The 1H-1H COSY spectrum of 1 exhibited 15 spin systems, as shown in bold lines in Figure 2. In the HMBC spectrum, the correlations of H3-29 to C-3/C-4/C-5/C-28, H3-19 to C-1/C-5/C-9/C-10, H3-30 to C-7/C-8/C-9/C-14, H3-18 to C-12/C-13/C-14/C-17, H-28 to C-6, as well as H-16a to C-14 led to the fused 5-rings moiety of unit A. In addition, the HMBC cross-peaks of H-21 to C-17/C-20/C-22, OH-22 to C-20/C-22, and H-23 to C-21 revealed the presence of a tetrahydrofuran moiety at C-17. In unit B, the oleanane skeleton was verified by the HMBC correlations of H3-24′ to C-3′/C-4′/C-5′/C-23′, H3-25′ to C-1′/C-5′/C-9′/C-10′, H3-26′ to C-7′/C-8′/C-9′/C-14′, H3-27′ to C-8′/C-13′/C-14′/C-15′, H3-29′ to C-19′/C-20′/C-21′/C-30′, H-19′ to C-13′/C-17′/C-18′, H-16′a to C-17′/C-28′, H-22′a to C-17′/C-28′ as well as H-1′b to C-3. The planned structure of unit C was also elucidated in similar ways to unit B.
Finally, the HMBC correlations of H-21/C-28′ and H-23/C-28′′ provided that units A and B, as well as units A and C were connected via C-21-C-28′ and C-23-C-28′′ bonds, respectively.
The relative configuration of 1 was elucidated by ROESY (Supplemental Figure S4) correlations and 3J coupling constants.
In unit A, the ROESY correlations of H-9 and H-5/H3-18 suggested that these protons were cofacial, while the correlations of H3-29 and H3-19/H-28, as well as H-6 and H3-19/H3-30, indicated that C-19, C-29, C-30, H-6, and H-28 were β-oriented (Figure 3). Also, the 3J coupling constants between H-5 and H-6 (12.8 Hz), as well as between H-6 and H-7 (2.8 Hz), supported the β-orientation of H-7. Furthermore, the ROESY correlations of H-21 and H-12b/H3-18, H-16b and H3-18/H-22, as well as H3-18 and OH-20, and coupling constants between H-16b and H-17 (12.9 Hz), as well as H-22 and H-23 (0 Hz) confirmed the stereochemistry of the tetrahydrofuran moiety.
Selected ROESY correlations and 3JH,H coupling constants for unit A of 1.
In unit B, C-24′, C-25′, C-26′, and H-13′ were assigned to be β-axially oriented from the ROESY correlations of H3-25′ and H3-24′/H3-26′, as well as H3-26′ and H-13′, while H-5′, H-9′, C-27′, H-16′a, H-22′a, and C-29′ were deduced to possess α-orientation from the ROESY correlations of H-5′ and H3-23′/H-9′, H3-27′ and H-9′/H-16′a, as well as H-22′ and H-16′a/H3-29′ (Figure 4). Thus, the relative configuration of unit B was identified as the ester form of moronic acid.21 Similar ROESY correlations were observed in unit C.
Selected ROESY correlations for unit B of 1.
Finally, the ROESY correlations of H-23 and H-13′/H3-26′, as well as OH-20 and H3-26′′, confirmed the stereochemistry of each unit of 1 (Figure 5).
Selected ROESY correlations of 1.
Treatment of 1 with LiOH gave a hydrolysate, whose spectral data and [α]D value {[α] : + 68 (c 1.0, CHCl3)} were identical to those of moronic acid {[α]D: + 29 (c 0.41, CHCl3)}.21 Thus, the absolute stereochemistry of 1 was assigned as shown in Figure 1.
The antimalarial activity of 1 was evaluated in vitro against Plasmodium falciparum 3D7 strain. The result showed that 1 possessed moderate antimalarial activity, with an IC50 value of 2.6 μM.
Experimental
General experimental procedures: Optical rotations were measured on a JASCO P-1030 polarimeter, UV spectra on a Shimadzu UVmini-1240 spectrophotometer, and IR spectra on a JASCO FT/IR-230 using Zn/Se cell. High-resolution ESI MS were obtained on a Waters Xevo G2-XS QTof LC/MS spectrometer using a sample dissolved in MeOH. 1H and 2D NMR spectra were measured on a 600 MHz spectrometer at 300 K, while 13C NMR spectra were measured on a 150 MHz spectrometer. The residual solvent peaks were used as internal standards (δH 7.26 and δC 77.0 for CDCl3). Standard pulse sequences were used for the 2D NMR experiments. Column chromatography was performed using silica gel 60 (230-400 mesh; Merck KGaA, Darmastadt, Germany), ODS (Cosmosil 140C18-OPN; Nacalai tesque, Inc., Kyoto, Japan), and Sephadex LH-20 (GE Healthcare, Sweden).
Plant materials: The barks of Chisocheton ceramicus Miq. were collected in July 2013 from Terengganu, Malaysia. Botanical identification was made by Prof. A. Hamid A. Hadi, University of Malaya. A voucher specimen (No. Hoshi13CCB) was deposited in the Department of Pharmacognosy, Hoshi University.
Extraction and Isolation: The dried barks of C. ceramicus (8 kg) were extracted with MeOH, and the extract (1247 g) was successively partitioned with n-hexane, EtOAc, n-butanol, and water. The hexane-soluble materials were subjected to column chromatograph (CC) over silica gel and eluted with hexane/EtOAc (1:0 to 1:1) followed by CHCl3/MeOH (1:0 to 0:1) to give 10 fractions (A-J). Fraction H was further separated by Sephadex LH-20 with CHCl3/MeOH (1:1) to afford 5 fractions (HA-HE). Fraction HC was separated by ODS CC with MeOH/H2O (9:1) continued with MeOH/Acetone (1:0 to 0:1) to give 7 fractions (HCA-HCG). Fraction HCE was then successively purified using a silica gel column with CHCl3/MeOH (1:0 to 0:1) and a silica gel column with benzene/EtOAc (9:1 to 4:1) to yield bismoronic ceramicine (1, 17.7 mg, 0.00022%).
Bismoronic ceramicine (1)
Colorless amorphous solid.
[α]: + 28 (c 1.0, CHCl3).
IR νmax (film): 3450, 1735, and 1703 cm−1.
UV (MeOH) λmax 203 (ε 15500) nm.
CD (MeOH) λmax 321 (Δε -0.49), 278 (Δε + 0.79), and 222 (Δε −7.79) nm.
HRESIMS m/z: 1379.9288 [M + H]+ (calcd. for C87H127O13, 1379.9277).
Hydrolysis of 1: To a solution of 0.5 mg of 1 in THF (0.5 mL) was added 0.5 mL LiOH aq. (2 mM). The mixture was stirred at 40 °C for 1 h. The mixture was added to n-hexane and partitioned. The water layer was extracted with CHCl3. After evaporation of the CHCl3 layer, moronic acid (1a) was obtained. 1a: Colorless amorphous solid; [α] : + 68 (c 1.0, CHCl3); 1H NMR (CDCl3): see Supplemental Figure S7; ESIMS m/z: 455 [M + H]+.
Parasite strain and culture: P. falciparum laboratory strain 3D7 was obtained from Prof. Masatsugu Kimura (Osaka City University, Osaka, Japan). For the assessment of antimalarial activity of the compound in vitro, the parasites were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 0.5 g/L L-glutamine, 5.96 g/L HEPES, 2 g/L sodium bicarbonate (NaHCO3), 50 mg/L hypoxanthine, 10 mg/L gentamicin, 10% heat-inactivated human serum, and red blood cells (RBCs) at a 3% hematocrit in an atmosphere of 5% CO2, 5% O2, and 90% N2 at 37 °C, as previously described.22 RBCs infected with ring-form parasites were collected using the sorbitol synchronization technique.23 Briefly, the cultured cells were collected by centrifugation at 840 g for 5 min at room temperature, suspended in a 5-fold volume of 5% D-sorbitol (Nacalai Tesque, Kyoto, Japan) for 10 min at room temperature, and then washed twice with RPMI 1640 medium to remove the D-sorbitol. The utilization of blood samples of healthy Japanese volunteers for the parasite culture was approved by the institutional review committee of the Research Institute for Microbial Diseases (RIMD), Osaka University (approval number: 22-3).
Antimalarial activity: Ring-form-synchronized parasites were cultured with 1 at sequentially decreasing concentrations (50, 15, 5, 1.5, 0.5, and 0.15 µM) for 48 h. Parasitemia was measured by flow cytometric analysis using an automated hematology analyzer, XN-30. The analyzer was equipped with a prototype algorithm for cultured falciparum parasites (software version: 01-03, build 16) and used specific reagents (CELLPACK DCL, SULFOLYSER, Lysercell M, and Fluorocell M) (Sysmex, Kobe, Japan).24,25 Approximately 100 µL of the culture suspension diluted with 100 µL phosphate-buffered saline was added to a BD Microtainer MAP Microtube for Automated Process K2 EDTA 1.0 mg tube (Becton Dickinson and Co., Franklin Lakes, NJ, USA) and loaded onto the XN-30 analyzer with an auto-sampler, as described in the instrument manual (Sysmex). The parasitemia (MI-RBC%) was automatically reported.24 DMSO (0.5%) alone or containing 5 µM artemisinin were used as the negative and positive controls, respectively. The growth inhibition (GI) rate was calculated from the MI-RBC% according to the following equation:
GI (%) = 100 – (test sample – positive control)/(negative control – positive control) × 100
The IC50 was calculated from GI (%) using GraphPad Prism version 9.0 (GraphPad Prism Software, San Diego, CA, USA).26
Supplemental Material
sj-docx-1-npx-10.1177_1934578X211053202 - Supplemental material for A Novel Trimeric Triterpene From
Chisocheton ceramicusMiq.
Supplemental material, sj-docx-1-npx-10.1177_1934578X211053202 for A Novel Trimeric Triterpene From
Chisocheton ceramicusMiq. by Alfarius Eko Nugroho, Marika Okabe, Yusuke Hirasawa and
Chin Piow Wong, Toshio Kaneda, Takahiro Tougan, Toshihiro Horii, Hiroshi Morita in Natural Product Communications
Footnotes
Acknowledgments
We thank Prof. Masatsugu Kimura (Osaka City University, Osaka, Japan) for the kind gift of the 3D7 strain, Mr Yuji Toya and Dr Kinya Uchihashi (Sysmex) for the setting of the XN-30 analyzer, and Ms Toshie Ishisaka and Ms Sawako Itagaki for their technical assistance. We also thank the Centre for Plant Conservation Botanic Gardens, Bogor, Indonesia, for providing and verifying the plant materials.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partly supported by JSPS KAKENHI Grant Number JP19K07152, Japan.
Ethical Approval
Not applicable, because this article does not contain any studies with human or animal subjects.
Informed Consent
Not applicable, because this article does not contain any studies with human or animal subjects.
ORCID iDs
Alfarius Eko Nugroho
Hiroshi Morita
Trial Registration
Not applicable, because this article does not contain any clinical trials.
Supplemental material
Supplemental material for this article is available online.
References
1.
TanQGLuoXD. Meliaceous limonoids: chemistry and biological activities. Chem Rev. 2011;111(11):7437-7522.
2.
NeboLVarelaRMMolinilloJMG, et al. Phytotoxicity of triterpenes and limonoids from the Rutaceae and Meliaceae. 5α,6β,8α,12α-tetrahydro-28-norisotoonafolin - a potent phytotoxin from Toona ciliata. Nat Prod Commun. 2018;10(1):17-20.
3.
Vieira MGCurcinoBraz-FilhoRCurcino VieiraIJ. Curcinomarcoide, a novel limonoid from Trichilia hirta (Meliaceae)-complete 1H and 13C chemical shift assignments. Nat Prod Commun. 2019;14(5). doi: 1934578X19843611
4.
NagakuraYYamanakaRHirasawaY,et al.Gaudichaudysolin A, a new limonoid from the bark of Dysoxylum gaudichaudianum. Heterocycles. 2010;80(2):1471-1477.
5.
InoueTMatsuiYKikuchiT, et al. Guianolides A and B, new carbon skeletal limonoids from the seeds of Carapa guianensis. Org Lett. 2013;15(12):3018-3021.
6.
FowlesRBMootooBSRamsewakRSReynoldsWFNairMGG. Limonoids from Meliaceae with lipid peroxidation inhibitory activity. Nat Prod Commun. 2011;6(6):785-787.
7.
NugrohoAEOnoYJinE, et al. Bisindole alkaloids from Voacanga grandifolia leaves. J Nat Med. 2021;75(2):408-414.
8.
HirasawaYAgawa-KakimotoMZaimaKUchiyamaNGodaYMoritaH. Complanadine F, a novel dimeric alkaloid from Lycopodium complanatum. J Nat Med. 2021;75(2):403-407.
9.
NugrohoAEHirasawaYKanedaT, et al. Triterpenoids from Walsura trichostemon. J Nat Med. 2021;75(2):415-422.
10.
AmeliaPNugrohoAEHirasawaY, et al. Two new bisindole alkaloids from Tabernaemontana macrocarpa jack. J Nat Med. 2021;75(3):633-642.
11.
NugrohoAENakajimaSWongCP, et al. Walsogynes H-O from Walsura chrysogyne. J Nat Med. 2021;75in press. doi: 10.1007/s11418-021-01556-4
12.
HirasawaYTanakaTHirasawaS, et al. Cliniatines A-C, new Amaryllidaceae alkaloids from Clivia miniata, inhibiting acetylcholinesterase. J Nat Med. 2021;75in press. doi: 10.1007/s11418-021-01570-6
13.
MohamadKHirasawaYLimCS, et al. Ceramicine A and walsogyne A, novel limonoids from two species of Meliaceae. Tetrahedron Lett. 2008;49(27):4276-4278.
14.
MohamadKHirasawaYLitaudonM, et al. Widyawaruyanti A, zaini NC, morita H. Ceramicines B–D, new antiplasmodial limonoids from Chisocheton ceramicus. Bioorg Med Chem. 2009;17(2):727-730.
15.
WongCPShimadaMNagakuraY, et al. Ceramicines E–I, new limonoids from Chisocheton ceramicus. Chem Pharm Bull. 2011;59(3):407-411.
16.
WongCPShimadaMNugrohoAE, et al. Ceramicines J–L, new limonoids from Chisocheton ceramicus. J Nat Med. 2012;66(3):566-570.
17.
NugrohoAEHashimotoAWongCP, et al. Ceramicines M-P from Chisocheton ceramicus: isolation and structure-activity relationship study. J Nat Med. 2018;72(1):64-72.
18.
WongCPDeguchiJNugrohoAEKanedaTHadiAHAMoritaH. Ceramicines from Chisocheton ceramicus as lipid-droplets accumulation inhibitors. Bioorg Med Chem Lett. 2013;23(6):1786-1788.
19.
WongCPKanedaTHadiAHAMoritaH. Ceramicine B, a limonoid with anti-lipid droplets accumulation activity from Chisocheton ceramicus. J Nat Med. 2014;68(1):22-30.
20.
IijimaCWongCPNugrohoAE, et al. Anti-melanin deposition activity of ceramicines from Chisocheton ceramicus. J Nat Med. 2016;70(4):702-707.
21.
MajumderPLMaitiRNPandaSKMalD. Carbon-13 nuclear magnetic resonance spectoscopy of naturally occurring substances. 64. Structure of moronic acid. J Org Chem. 1979;44(15):2811-2812.
22.
TragerWJensenJB. Human malaria parasites in continuous culture. Science. 1976;193(4254):673-675.
23.
LambrosCVanderbergJP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65(3):418-420.
24.
TouganTSuzukiYItagakiS, et al. An automated haematology analyzer XN-30 distinguishes developmental stages of falciparum malaria parasite cultured in vitro. Malar J. 2018;17:59. doi:10.1186/s12936-018-2208–6
25.
ToyaYTouganTHoriiTUchihashiK. Lysercell M enhances the detection of stage-specific Plasmodium-infected red blood cells in the automated hematology analyzer XN-31 prototype. Parasitol Int. 2021;80:102206. doi:10.1016/j.parint.2020.102206
26.
TouganTToyaYUchihashiKHoriiT. Application of the automated haematology analyzer XN-30 for discovery and development of anti-malarial drugs. Malar J. 2019;18(1):8. doi:10.1186/s12936-019-2642-0
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.